Disulfiram Treatment Study at Columbia University - Global Lyme Alliance Disulfiram Treatment Study at Columbia University - Global Lyme Alliance

A New Treatment Study for Previously Treated Lyme Disease Patients with Persistent Fatigue

Were you previously treated for Lyme disease and still experience persistent fatigue? If so, you may qualify for a clinical trial investigating the effectiveness of disulfiram in treating patients with post-treatment Lyme disease.

Eligibility Criteria

Condition:
Diagnosed with Lyme disease and experiencing chronic fatigue that began after being diagnosed and treated with antibiotics (at least 5 weeks) within the last 16 years.
Age:  18 years to 65 years
Gender:  All

About the Study

Are you suffering from chronic fatigue that began after you were diagnosed and treated with antibiotics for Lyme Disease? This new treatment research study investigates whether disulfiram, commonly known as “Antabuse”, has the potential to be used as a treatment option for patients experiencing chronic post-treatment Lyme symptoms. This well-known, FDA approved drug is currently used to help individuals with alcohol dependence resist consumption; however, new scientific research has demonstrated that disulfiram is a potent killer of the Lyme bacteria in the laboratory setting. The primary goals of this study are to assess safety, side-effects, and effectiveness of disulfiram in reducing symptoms in patients with post-treatment Lyme symptoms. This study will take place over the course of 16 weeks with 8 in-person visits to our Lyme Center and several phone follow-ups. Participants will be placed on either a 4-week or 8-week, fixed flexible dosing regimen.

How Do I Participate?

If you’d like to learn more about the study and how to participate, visit

 
Find
Find a Clinical
Trial
Preload
Translate »